Dordaviprone

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H26N4O
Molecular Weight	386.4894
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of Dordaviprone

Structure Search

SMILES

CC1=CC=CC=C1CN2C3=NCCN3C4=C(CN(CC5=CC=CC=C5)CC4)C2=O

InChI

InChIKey=VLULRUCCHYVXOH-UHFFFAOYSA-N

InChI=1S/C24H26N4O/c1-18-7-5-6-10-20(18)16-28-23(29)21-17-26(15-19-8-3-2-4-9-19)13-11-22(21)27-14-12-25-24(27)28/h2-10H,11-17H2,1H3

HIDE SMILES / InChI

Molecular Formula	C24H26N4O
Molecular Weight	386.4894
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 20:21:39 UTC 2023` Edited by `admin` on `Sat Dec 16 20:21:39 UTC 2023`
Record UNII	9U35A31JAI
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Dordaviprone

Official Name

English

ONC201

Code

English

TIC-10

Code

English

dordaviprone [INN]

Common Name

English

7-benzyl-4-[(2-methylphenyl)methyl]-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one

Systematic Name

English

Imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, 2,4,6,7,8,9-hexahydro-4-[(2-methylphenyl)methyl]-7-(phenylmethyl)-

Systematic Name

English

TIC10

Code

English

2,4,6,7,8,9-Hexahydro-4-[(2-methylphenyl)methyl]-7-(phenylmethyl)imidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one

Systematic Name

English

DORDAVIPRONE [USAN]

Common Name

English

ONC 201 [WHO-DD]

Common Name

English

ONC-201

Code

English

NSC-350625

Code

English

Classification Tree Code System Code

FDA ORPHAN DRUG

553316

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

FDA ORPHAN DRUG

640218

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

Code System Code Type Description

USAN

LM-148

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

PRIMARY

CAS

1342897-86-2

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

SUPERSEDED

NCI_THESAURUS

C113792

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

PRIMARY

PUBCHEM

73777259

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

PRIMARY

FDA UNII

9U35A31JAI

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

PRIMARY

INN

12147

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

PRIMARY

SMS_ID

300000017123

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

PRIMARY

CAS

1616632-77-9

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

PRIMARY

DRUG BANK

DB14844

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

PRIMARY

NSC

350625

Created by admin on Sat Dec 16 20:21:40 UTC 2023 , Edited by admin on Sat Dec 16 20:21:40 UTC 2023

PRIMARY

Related Record Type Details


					53VG71J90J

Dordaviprone Hydrochloride

SALT/SOLVATE -> PARENT

Amount:


					19GBD6T9L7

D(2) DOPAMINE RECEPTOR

TARGET -> INHIBITOR

Interaction Type:

ANTAGONIST

Amount:

Related Record Type Details


					9U35A31JAI

ACTIVE MOIETY

Comments:

Experiments showed that TIC10 had potent effects against a variety of tumours, including breast, lymphatic, colon and lung cancer. It was especially effective at triggering cell suicide in glioblastoma, a kind of brain tumour that is notoriously difficult to treat2. Mice with glioblastomas that were treated with TIC10 in combination with bevacizumab a drug used against diseases including brain tumours, and sold under the name Avastin survived three times as long as untreated mice. Even mice treated with TIC-10 alone still had better survival rates (6% longer) than those treated with bevacizumab alone.

Amount: